Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Homozygous Trem2 C.549Del; P.(Leu184serfs*5) Variant Causing Nasu-Hakola Disease in Three Siblings in a Consanguineous Iraqi Family: Case Report and Review of Literature Publisher Pubmed



Gilani N1, 2 ; Bitarafan F3 ; Ozaslan M1 ; Asheim S3 ; Heidari M4 ; Garshasbi M5
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Biology, Gaziantep University, Gaziantep, Turkey
  2. 2. Farabi Molecular Laboratory, Irbil, Iraq
  3. 3. Department of Medical Genetics, Oslo University Hospital and University of Oslo, Oslo, Norway
  4. 4. Myelin Disorders Clinic, Department of Pediatric Neurology, Children's Medical Center, Pediatrics Center of Excellence, Tehran University of Medical Sciences, Tehran, Iran
  5. 5. Department of Medical Genetics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran

Source: Molecular Genetics and Genomic Medicine Published:2024


Abstract

Background: The Triggering Receptor Expressed on Myeloid Cells 2 protein (TREM2) plays a crucial role in various biological processes, including osteoclast differentiation, and disease-associated microglia (DAM) activation to regulate neuroinflammation, and phagocytosis in the brain. Genetic variations in TREM2 are implicated in neurodegenerative disorders, such as Nasu-hakola disease (NHD), characterized by bone lesions, neuropsychiatric disorders, and early-onset dementia. Methods: We studied 3 siblings with suspected NHD. Whole-exome sequencing was conducted on the proband to identify the possible genetic cause(s) and by Sanger sequencing to validate the identified variants in the two other affected siblings, a healthy sister, and the parents. Results: We identified a novel homozygous deletion (c.549del; p.(Leu184Serfs*5)) in TREM2. Our literature review reveals 16 TREM2 mutations causing early-onset dementia and bone lesions. Conclusion: These findings, alongside previous research, elucidate the clinical spectrum of TREM2-related diseases, aiding accurate diagnosis and patient care. This knowledge is vital for understanding TREM2-dependent DAM and its involvement in the pathogenesis of neurodevelopmental disorders which can help to develop targeted therapies and improve outcomes for TREM2-affected individuals. © 2024 The Author(s). Molecular Genetics & Genomic Medicine published by Wiley Periodicals LLC.
Related Docs
Experts (# of related papers)